Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates - Toronto Sunnybrook Regional Cancer Centre experience

Supportive Care in Cancer

Volumn 12, Issue 1, 2004, Pages 48-52

  Enright, Katherine ^a   Clemons, Mark ^b   Chow, Edward ^c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Bisphosphonates; Bone metastases; Breast cancer; Palliative radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; PAMIDRONIC ACID; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BONE CANCER; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLODRONIC ACID; DIPHOSPHONATES; EXTREMITIES; FEMALE; HUMANS; MIDDLE AGED; ONTARIO; PALLIATIVE CARE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SPINE; TREATMENT OUTCOME;

EID: 1642430621     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-003-0548-3     Document Type: Article

References (32)

1. Berenson JR, Lipton A, Rosen CJ, et al (1998) Phase I clinical study of a new bisphosphonate, zoledronate (CGP-42446), in patients with osteolytic bone metastases. Blood [Suppl 1] 88:586a
2. Bessler W, Weber S (1977) Die. Strahlenbehandlung von Knochenmetastasen bei Mammacarcinom. Schweiz Rundsch Med Prax 66:140
3. Body JJ, Bartl R, Bruckhardt P for the International Bone and Cancer Study Group: Current use of bisphosphonates in oncology (1998) J Clin Oncol 16:3890-3899
4. Body JJ, Lichinister MR, Diehl IE et al (1999) Double-blind placebo controlled trial of ibandronate in breast cancer metastatic to bone. Proc Am Soc Clin Oncol 18:575a
5. Bone Pain Trial Working Party (1999) 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomized comparison with multi-fraction schedule over 12 months of patient follow-up. Radiother Oncol 52:111-121
6. Breast Cancer Disease Site Group (2000) Use of bisphosphonates in patients with bone metastases from breast cancer. CCO Practice Guideline Initiative. Available at http://www.hiru. mcmaster.ca/ccopgi/guidelines/bre/ cpg1_11.html
7. Coleman R (1997) Skeletal complications of malignancy. Cancer 80:1588-1594
8. Coleman R, Rubens R (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55:61-66
9. Conte P, Latreille L, Mauriac L, et al (1996) Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 14:2552-2559
10. Diel I (1999) Continual PO versus IV interval therapy with bisphosphonates in patients with breast cancer and bone metastases. Proc Am Soc Clin Oncol. Abstract 488
11. Diel I, Solomayer E, Costa S, Gollan C, Goerner R, Wallwiener D, et al (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357-363
12. Elomaa I, Blomqvist C, Grohn P, et al (1983) Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1:146-149
13. Elomaa I, Blomqvist C, Porkka L, et al (1987) Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone 8:S53-S56
14. Garmatis GJ, Chu FCH (1978) The effectiveness of radiation therapy in the treatment of bone metastases from breast cancer. Radiology 126:235
15. Hill M, Richards M, Gregory W, Smith P, Rubens R (1993) Spinal cord compression in breast cancer: a review of 70 cases. Br J Cancer 68:969-973
16. Hillner BE, Ingle JN, Berenson JR et al (2000) American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 18:1378-1391
17. Hortobagyi G, Theriault R, Porter L, Blayney D, Lipton A, Sinoff C, et al (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335:1785-1791
18. Hortobagyi G, Theriault R, Lipton A, Porter L, Blayney D, Sinoff C, et al (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16:2038-2044
19. Hoskin PJ, Price P, Easton D, et al (1992) A prospective randomized trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother Oncol 23:74-78
20. Koswig S, Budach V (1999) Remineralization and pain relief in bone metastases after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy). A prospective study [in German]. Strahlenther Onkol 175:500-508
21. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88(5):1082-90
22. Martoni A, Guaraldi M, Camera P, et al (1991) Controlled clinical study on the use of dichloromethylene diphosphate in patients with breast carcinoma metastasizing to the skeleton. Oncology 48:97-101
23. Mundy G (1997) Mechanisms of bone metastasis. Cancer 80:1546-1556
24. Paterson A, Powles T, Kanis J, McCloskey E, Hanson J, Ashley S (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65
25. Price P, Hoskin P, Easton D, et al (1986) Prospective randomized trial of single and multi-fraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 6:247-255
26. Rubens R (1998) Bone metastases-the clinical problem. Eur J Cancer 34:210-213
27. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Glück S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ, for the Protocol 18 Aredia Breast Cancer Study Group (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol (17)3:846-854
28. van Holten-Verzantvoort A, Bijvoet O, Cleton F, et al (1987) Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 2:983-985
29. van Holten-Verzantvoort A, Zwinderman A, Aaronson N, et al (1991) The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer 27:544-549
30. van Holten-Verzantvoort A, Kroon H, Bijvoet O, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology 1993; 11:491-498
31. Wong R, Wiffen J (2002) Bisphosphonates for the relief of pain secondary to bone metastases. In: The Cochrane Library, Oxford
32. Wu J, Wong R, Johnston M, et al (2003) Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Rad Oncol Biol Phys 55(3):594-605